Trinity Biotech (TRIB) Debt to Equity (2009 - 2024)

Trinity Biotech has disclosed Debt to Equity across 10 years of filings, most recently posting -$2.1 for Q4 2024.

• Debt to Equity for Q4 2024 came in at -$2.1, down 24.05% year-over-year; the trailing twelve-month figure through Dec 2024 was -$2.1 (down 24.05% YoY), and the FY2024 annual result was -$2.1, down 24.05% from the prior year.
• Debt to Equity came in at -$2.1 for Q4 2024 at Trinity Biotech, down from -$1.7 in the prior quarter.
• In the past five years, Debt to Equity ranged from a high of $6.91 in Q3 2022 to a low of -$21.08 in Q4 2022.
• The 5-year median for Debt to Equity is -$0.9 (2021), against an average of -$3.02.
• Across the five-year window, Debt to Equity slumped 21591.96% in 2022 and jumped 91.95% in 2023, its largest moves.
• Trinity Biotech's Debt to Equity stood at -$0.03 in 2020, then plunged by 275.55% to -$0.1 in 2021, then plunged by 21591.96% to -$21.08 in 2022, then surged by 91.95% to -$1.7 in 2023, then retreated by 24.05% to -$2.1 in 2024.
• The last three Debt to Equity figures came in at -$2.1 (Q4 2024), -$1.7 (Q4 2023), and -$21.08 (Q4 2022), per Business Quant data.